Sulfamethizole

Summary

Sulfamethizole (CHEMBL1191) is an approved small-molecule antimicrobial agent (ATC S01AB01); indicated across 3 conditions including bacterial infectious disease and eye infectious disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: S01AB01 (+3 more)
• Indications: 3 conditions
• Chemistry: 270.3 Da · C9H10N4O2S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1191
Name	Sulfamethizole
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5328
ChEBI	CHEBI:9331
ATC	S01AB01, D06BA04, J01EB02, B05CA04
Molecular formula	C9H10N4O2S2
Molecular weight	270.3
InChIKey	VACCAVUAMIDAGB-UHFFFAOYSA-N

SMILES: CC1=NN=C(S1)NS(=O)(=O)C2=CC=C(C=C2)N

IUPAC name: 4-amino-N-(5-methyl-1,3,4-thiadiazol-2-yl)benzenesulfonamide

ChEBI definition: A sulfonamide consisting of a 1,3,4-thiadiazole nucleus with a methyl substituent at C-5 and a 4-aminobenzenesulfonamido group at C-2.

Pharmacological roles (ChEBI): antimicrobial agent, EC 2.5.1.15 (dihydropteroate synthase) inhibitor, antiinfective agent, drug allergen.

Also known as: Microsul, Methazol, NSC-757327, Proklar, Sulfamethizol, Sulfamethizole, Sulfametizol, Sulphamethylthiadiazole, Thiosulfil, Tetracid, Urolucosil, Sulfamethiazole

Patent coverage: 5,085 distinct patent families (16,793 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Prelamin-A/C, Beta-lactamase, Aldehyde dehydrogenase 1A1, Lethal factor.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	5.35	Potency	4467	nM	CHEMBL_ACT_3652140

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
eye infectious disorder	4	MONDO:0043885	EFO:1001888
osteomyelitis	0	MONDO:0005246	EFO:0003102

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).